Children’s Medical Center has been granted a patent for an immunogenic composition that utilizes a biotinylated polysaccharide to non-covalently associate with multiple peptide or polypeptide antigens. This system aims to elicit both humoral and cellular immune responses against various pathogens simultaneously. GlobalData’s report on Children’s Medical Center gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Children's Medical Center, was a key innovation area identified from patents. Children's Medical Center's grant share as of June 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Immunogenic composition with multiple distinct peptide antigens
The granted patent US11981708B2 describes an innovative immunogenic composition that includes 5-10 distinct peptide or polypeptide antigens organized into various species of immunogenic complexes. Each complex features a biotinylated polysaccharide antigen and a fusion protein that consists of a biotin-binding protein and at least one of the specified peptide or polypeptide antigens. The biotinylated polysaccharide antigen is non-covalently associated with the biotin-binding protein, ensuring that the composition contains immunologically effective amounts of both components. The patent outlines that upon administration, the polysaccharide antigen can elicit an immune response, which may include humoral, cellular, antibody, or T cell responses.
Additionally, the patent specifies that the biotin-binding protein can be rhizavidin or a modified version of it, and at least one of the peptide or polypeptide antigens may originate from pathogenic organisms or tumors, including specific antigens from Streptococcus pneumoniae. The polysaccharide antigens can include a variety of types, such as those from Salmonella typhi, pneumococci, and other notable pathogens. The patent also covers a pharmaceutical composition that incorporates the immunogenic composition along with a pharmaceutically acceptable carrier, as well as methods for inducing an immune response in subjects and for manufacturing the immunogenic composition through the combination and purification of its components.
To know more about GlobalData’s detailed insights on Children's Medical Center, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
